COMPANY

Basking Biosciences

Keywords: thrombosis Pharmacodynamics Acute Ischemic Stroke BB-031 BB-025 DTRI-031

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Undisclosed round · $55M · announced Jan 30, 2024 Company release ↗
Source quote
- Jan 30, 2024 · Company release ↗
  “Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy to treat stroke, today announced the close of a $55 million financing”

Raises announced in these releases: $55M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Nov 5, 2025 Trial start Phase 1: Study of BB-025, Alone and After BB-031, in Healthy Volunteers source ↗
Jul 31, 2024 Trial start Phase 2: Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) source ↗
Jan 30, 2024 Raise Undisclosed round · $55M source ↗
Oct 20, 2021 Trial start Phase 1: Study of DTRI-031 in Healthy Volunteers source ↗

2027-06 (ESTIMATED) · Phase 2 · Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) · NCT06226805

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06226805	Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)	Phase 2	Recruiting	Jul 31, 2024	2027-06 (estimated)
NCT07202663	Study of BB-025, Alone and After BB-031, in Healthy Volunteers	Phase 1	Completed	Nov 5, 2025	Mar 18, 2026 (actual)
NCT05005520	Study of DTRI-031 in Healthy Volunteers	Phase 1	Completed	Oct 20, 2021	Apr 19, 2022 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗